Scarica l'app Stockscreener
2.80
3.32%
0.09
Dopo l'orario di chiusura:
3.20
0.40
+14.29%
Precedente Chiudi:
$2.71
Aprire:
$2.71
Volume 24 ore:
1.38M
Relative Volume:
3.56
Capitalizzazione di mercato:
$294.60M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-7.3918
EPS:
-0.3788
Flusso di cassa netto:
$21.84M
1 W Prestazione:
+12.00%
1M Prestazione:
+40.70%
6M Prestazione:
+145.61%
1 anno Prestazione:
-30.35%
Intervallo 1D:
$2.61
$3.00
Intervallo di 1 settimana:
$2.20
$3.00
Portata 52W:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Confronta PRQR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.80 | 259.15M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
ProQR Therapeutics N.V. stock retracement – recovery analysisPortfolio Value Summary & Stepwise Trade Execution Plans - newser.com
What catalysts could drive ProQR Therapeutics N.V. stock higher2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
What drives ProQR Therapeutics NV stock priceSector Leadership Analysis & Double Digit Portfolio Growth - earlytimes.in
Will ProQR Therapeutics N.V. stock outperform international peersPortfolio Return Summary & Short-Term Trading Alerts - newser.com
Is ProQR Therapeutics N.V. stock a good choice for value investorsWeekly Stock Analysis & Free Weekly Watchlist of Top Performers - newser.com
ProQR stock rating reiterated at Market Outperform by Citizens - Investing.com
Key metrics from ProQR Therapeutics N.V.’s quarterly dataInflation Watch & Fast Exit and Entry Strategy Plans - newser.com
Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - The Globe and Mail
How moving averages guide ProQR Therapeutics N.V. tradingQuarterly Trade Report & Technical Entry and Exit Tips - newser.com
Risk adjusted return profile for ProQR Therapeutics N.V. analyzedJuly 2025 Update & Community Supported Trade Ideas - newser.com
ProQR Therapeutics to Participate in Upcoming Investor Conferences with Focus on RNA Editing Technology - Quiver Quantitative
ProQR to Participate in Upcoming Investor Conferences in October 2025 - GlobeNewswire
Oct 14–22, 2025: ProQR to Present at Three Investor Conferences; RNA Editing Panel Oct 21, webcasts available - Stock Titan
ProQR Therapeutics N.V. stock chart pattern explainedWeekly Profit Recap & AI Optimized Trade Strategies - newser.com
Quantitative breakdown of ProQR Therapeutics N.V. recent moveMarket Movement Recap & Fast Entry and Exit Trade Plans - newser.com
Risk vs reward if holding onto ProQR Therapeutics N.V.2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
ProQR Therapeutics' (PRQR) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With Revenues - simplywall.st
How ProQR Therapeutics N.V. (0PQ) stock reacts to new regulationsWeekly Trade Recap & Consistent Income Trade Recommendations - newser.com
Can you recover from losses in ProQR Therapeutics N.V.2025 Price Momentum & High Return Stock Watch Alerts - newser.com
What MACD and RSI say about ProQR Therapeutics N.V.Earnings Summary Report & Weekly High Potential Alerts - newser.com
Analyzing drawdowns of ProQR Therapeutics N.V. with statistical toolsDip Buying & Long-Term Growth Stock Strategies - newser.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
How to escape a deep drawdown in ProQR Therapeutics N.V.Breakout Watch & Weekly Chart Analysis and Guides - newser.com
Will ProQR Therapeutics N.V. (0PQ) stock outperform energy sector in 2025Portfolio Risk Report & Fast Exit Strategy with Risk Control - newser.com
Should you wait for a breakout in ProQR Therapeutics N.V.Day Trade & Stepwise Swing Trade Plans - newser.com
Order flow analysis tools used on ProQR Therapeutics N.V.Price Action & Daily Stock Momentum Reports - newser.com
What MACD signals say about ProQR Therapeutics N.V.Market Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):